Table 1 Distribution of nuclear and cytoplasmic YAP and TAZ positivity in human CCA subtypes
From: Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma
iCC (152) | YAP | TAZ | YAP or TAZ | YAP and TAZ |
nuclear | 60 (39.5%) | 48 (31.6%) | 66 (43.4%) | 21 (13.8%) |
cytoplasmic | 43 (28.3%) | 4 (2.6%) | 43 (28.3%) | 2 (1.3%) |
nuc. and cytopl. | 68 (44.7%) | 49 (32.2%) | 69 (45.4%) | 24 (15.8%) |
pCC (155) | YAP | TAZ | YAP or TAZ | YAP and TAZ |
nuclear | 65 (41.9%) | 55 (35.5%) | 50 (32.3%) | 35 (22.6%) |
cytoplasmic | 48 (31%) | 3 (1.9%) | 49 (31.6%) | 1 (0.6%) |
nuc. and cytopl. | 76 (49%) | 57 (36.8%) | 57 (36.8%) | 38 (24.5%) |
dCC (126) | YAP | TAZ | YAP or TAZ | YAP and TAZ |
nuclear | 37 (29.4%) | 83 (65.9%) | 62 (49.2%) | 29 (23%) |
cytoplasmic | 39 (31%) | 6 (4.8%) | 43 (34.1%) | 1 (0.8%) |
nuc. and cytopl. | 55 (43.7%) | 84 (66.7%) | 55 (43.7%) | 42 (33.3%) |